Back to results
US 2020/0369727 A1Published application
Composition and method for treating a patient having liver cirrhosis
AssigneeKing Abdulaziz University
InventorsMoustafa E. EL-ARABY, Abdelsattar Mansour Omar, Mahmoud Abdelkhalek El-Faky, Sameh Hamdy Abdelmageed Soror, Maan Talaat Khayat, Hani Zakariah Asfour, Faida Hassan Bamane
Life of this patent
Estimating the term…
Abstract
Peptide inhibitors of activation of hepatitis C virus (HCV) NS3 protease are disclosed. They are analogs of the activation peptide HCV NS4 of residues 21-33 of SEQ ID NO: 2 and contain non-proteinogenic amino acids. Competitive binding studies showed the peptide analogs bind HCV NS3 protease at the activation site.
Claims10
1-20. (canceled)
21:
- A peptide which has an amino acid sequence comprising SEQ ID NO:
- 20.
22:
- The peptide of claim 21 that is Pep-15 which has an amino acid sequence consisting of SEQ ID NO:
- 20.
23:
- A peptide conjugate comprising the peptide of claim 21 and polyethyelene glycol (“PEG”).
24:
- A composition comprising the peptide of claim 21 and a pharmaceutically acceptable carrier.
25:
- The composition of claim 24, wherein the peptide is present at a concentration ranging from 1.0 μM to 100 mM.
26:
- The composition of claim 24, further comprising at least one of oseltamivir, zanamivir, permivir, a dideoxynucleoside, azidothymadine, ribavirin, or interferon.
27:
- A method for treating a subject infected by hepatitis C virus (“HCV”) comprising administering the peptide of claim 21 to said subject.
28:
- The method of claim 27, wherein the subject is chronically infected with HCV.
29:
- The method of claim 27, wherein the subject has liver cirrhosis or hepatocellular carcinoma.